- Home
- NKTX
NKTX
Nkarta Inc.
as 02-21-2025 4:00pm EST
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 170.8M | IPO Year: | 2020 |
| Target Price: | $15.20 | AVG Volume (30 days): | 832.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.96 - $16.24 | Next Earning Date: | 03-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nkarta Inc. (NKTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hager Alicia J. | NKTX | Chief Legal Officer | Jan 15 '25 | Sell | $2.20 | 9,584 | $21,084.80 | 146,735 | |
| Shook David | NKTX | See Remarks | Jan 15 '25 | Sell | $2.20 | 8,638 | $19,003.60 | 190,955 | |
| Brandenberger Ralph | NKTX | Chief Technical Officer | Jan 15 '25 | Sell | $2.20 | 7,447 | $16,383.40 | 124,796 | |
| HASTINGS PAUL J | NKTX | Chief Executive Officer | Jan 15 '25 | Sell | $2.20 | 17,378 | $38,231.60 | 319,859 | |
| Levin Alyssa | NKTX | See Remarks | Jan 15 '25 | Sell | $2.20 | 5,838 | $12,843.60 | 102,662 |
Latest Nkarta Inc. News
NKTX Breaking Stock News: Dive into NKTX Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Nkarta Opens Enrolment, Receives Clearance for Autoimmune Diseases Therapy Trials
GlobeNewswire
3 months ago
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
GlobeNewswire
3 months ago
Nkarta to Participate in an Upcoming Investor Conference
TipRanks
3 months ago
Nkarta price target lowered to $16 from $20 at Mizuho
GlobeNewswire
3 months ago
Nkarta to Participate in an Upcoming Investor Conference
GlobeNewswire
3 months ago
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
Simply Wall St.
4 months ago
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
Benzinga
4 months ago
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Compare NKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTX Nkarta Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.